Oppenheimer analyst Jeff Jones lowered the firm’s price target on Seres Therapeutics to $5 from $9 and keeps an Outperform rating on the shares. The firm notes Seres reported Q4 and year-end results, with $10.4M in VOWST Q4 net sales, quarter-over-quarter growth of 27%, consistent with numbers pre-released in January. The financial contribution from VOWST to Seres remained negative for Q4, Oppenheimer adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MCRB:
- A New Cause for Concern: Seres Therapeutics Inc. Adds a New Supply Chain Risk
- Seres Therapeutics Inc. (MCRB) Q4 Earnings Cheat Sheet
- Seres Therapeutics Announces Executive Leadership Transition and New CFO Compensation Details
- Seres Therapeutics appoints Marella Thorell CFO amid Arkowitz retirement
- Seres Therapeutics Announces 2024 Virtual Stockholders Meeting
